Herpes simplex virus 2 (HSV-2) causes a persistent, lifelong infection that increases risk for sexually transmitted infection acquisition. Both the lack of a vaccine and the need for chronic suppressive therapies to control infection presents the need to further understand immune mechanisms in response to acute HSV-2 infection. The IL-36 cytokines are recently identified members of the IL-1 family and function as inflammatory mediators at epithelial sites. Here, we first used a well-characterized three-dimensional (3-D) human vaginal epithelial cell (VEC) model to understand the role of IL-36γ in the context of HSV-2 infection. In 3-D VEC, IL-36γ is induced by HSV-2 infection, and pretreatment with exogenous IL-36γ significantly reduced HSV-2 replication. To assess the impact of IL-36γ treatment on HSV-2 disease pathogenesis, we employed a lethal genital infection model. We showed that IL-36γ treatment in mice prior to lethal intravaginal challenge significantly limited vaginal viral replication, delayed disease onset, decreased disease severity, and significantly increased survival. We demonstrated that IL-36γ treatment transiently induced pro-inflammatory cytokines, chemokines, and antimicrobial peptides in murine lower female reproductive tract (FRT) tissue and vaginal lavages. Induction of the chemokines CCL20 and KC in IL-36γ treated mice also corresponded with increased polymorphonuclear (PMN) leukocyte infiltration observed in vaginal smears. Altogether, these studies demonstrate that IL-36γ drives the transient production of immune mediators and promotes PMN recruitment in the vaginal microenvironment that increases resistance to HSV-2 infection and disease. Our data indicate that IL-36γ may participate as a key player in host defense mechanisms against invading pathogens in the FRT.
Introduction
Genital herpes simplex virus 2 (HSV-2) infections remain one of the most common sexually transmitted infections (STI), affecting over 250 million women worldwide [1] . HSV-2 causes a persistent, lifelong infection that increases risk for STI acquisition, including human immunodeficiency virus [2] . Despite the availability of therapeutic interventions to limit HSV-2 disease, the virus can be transmitted through asymptomatic shedding and even during chronic suppressive therapy [3] [4] [5] .
The vaginal epithelium is a first-line of defense against acute genital HSV-2 infection, forming a physical barrier to infection. Initiation of innate immune signaling by vaginal epithelial cells is crucial for the production of pro-inflammatory cytokines, chemokines, and antimicrobial peptides (AMP) to control acute HSV-2 infection [6, 7] . These soluble immune mediators produced in the vaginal epithelium are vital components of the barrier to infection, and can protect against HSV-2 infection by blocking binding and entry [8] [9] [10] [11] . Despite our current understanding of host defense mechanisms, there still exists a need to understand underlying innate immune mechanisms in the vaginal epithelium that can inhibit virus replication during acute HSV-2 infection, and ultimately limit the spread and establishment of latency and recurrent HSV-2 disease. We have previously shown that interleukin (IL)-36γ, a novel pro-inflammatory cytokine, is expressed in the lower FRT and is induced in a Toll-like receptor (TLR)-mediated manner in response to microbial products, including the viral dsRNA mimic, poly (I:C) [12] . Additionally, we demonstrated that IL-36γ signals in an autocrine manner, creating a self-sustaining loop that amplifies IL-36γ and cytokine, chemokine, and AMP production in the FRT [12] .
Several studies have recently shown that the IL-36 cytokines, including IL-36α, -β, and -γ, are key inflammatory mediators in host defense against bacteria, fungi, and viruses at various epithelial sites [12] [13] [14] [15] [16] [17] [18] [19] . These family members share between 15 and 85% sequence https://doi.org/10.1016/j.cyto.2018.07.034 Received 25 April 2018; Received in revised form 10 July 2018; Accepted 30 July 2018 similarity at the amino acid level, with IL-36α and IL-36γ being the most similar among the cytokines [20] . Despite similarity among the three agonists, the differential expression patterns of the IL-36 family members suggest that these cytokines may have cell-and/or tissuespecific functions [21, 22] . IL-36α, -β, and -γ are all expressed in nonhematopoietic cells, including keratinocytes and mucosal epithelial cells, but are induced in response to different inflammatory stimuli [23] . For example, IL-36α and IL-36γ have been shown to be robustly induced in bronchial epithelial cells in response to microbial products, bacterial infection, and viral infection, suggesting that the IL-36 cytokines may play an important role in epithelial host defense [14, 18, 19, 24, 25] . Indeed, IL-36γ −/− mice exhibited delayed clearance of Streptococcus pneumoniae and Klebsiella pneumoniae in lung infections, decreased Th1 and Th17 cytokine levels, and increased mortality [18] . In Mycobacterium tuberculosis infections, IL-36γ promotes the production of AMPs that limit bacterial growth [13, 26] . In another study, it was found that IL-36R signaling and IL-36α promoted the production of immune mediators and increased influx of neutrophils and monocytes in response to influenza virus infection in the lungs, indicating that the IL-36 cytokines may have distinct functions in response to specific inflammatory stimuli [14] . It has been well documented that the viral RNA mimic poly(I:C) induces IL-36γ, further demonstrating that IL-36γ may play a role in host antiviral defense mechanisms [12, 27, 28] . However, IL-36β, but not IL-36α or IL-36γ, has been shown to protect against HSV-1 disease in keratinocytes and a flank skin infection model [20] . This finding indicates that the IL-36 cytokines may have site-specific functions in host defense.
In the upper female reproductive tract it has been shown that Listeria monocytogenes infection robustly induced the IL-36 cytokines in the uteri of pregnant mice, however, the impact of the IL-36 cytokines on infection and pregnancy is still unclear [29] . Recently, our laboratory measured increased levels of IL-36γ in cervicovaginal lavages (CVLs) from cervical cancer patients [30] . Additionally, clinical proteomic studies have also measured an increase in the relative abundance of IL-36γ in CVLs from HSV-2 seropositive Depo-Provera users [31] , and an increase in IL-36 cytokines in women with bacterial vaginosis [32] . Together, these studies suggest that IL-36γ may play an important role in host defense mechanisms in the FRT.
We aimed to better understand IL-36γ in the context of HSV-2, a clinically relevant viral STI. In this study, we utilized an innovative three-dimensional (3-D) human vaginal epithelial cell (VEC) model [33] and a lethal genital infection model to identify the extent to which IL-36γ impacts HSV-2 disease. We also investigated the level to which IL-36γ treatment modulated production of immune mediators and recruitment of immune cells in the vaginal microenvironment as potential mechanisms by which IL-36γ limits genital HSV-2 disease. Collectively, our data suggests that IL-36γ may participate as a key regulator of mucosal inflammation and host defense in the FRT.
Materials and methods

3-D VEC culture
Three-dimensional human vaginal epithelial (V19I) cells were cultured as previously described [12, 34, 35] . The V19I cell line was validated by short tandem repeat (STR) profiling and shown to be free of contamination from other cell lines. Briefly, V19I cells were combined with collagen-coated dextran microcarrier beads in a 1:1 mixture of supplemented keratinocyte serum free medium (KSFM) and EpiLife medium (Life Technologies, Grand Island, NY). Cell and bead mixtures were transferred to a slow turning lateral vessel bioreactor (Synthecon, Houston, TX) and incubated over a 28-day period at 37°C. Fully-differentiated aggregates were quantified and cell viability was measured by trypan blue exclusion using a Countess machine (Life Technologies). For all in vitro experiments, 3-D aggregates were transferred into 24-well plates (1 × 10 5 -5 × 10 5 cells/ml).
HSV-2 propagation and plaque assay
HSV-2 186 was generously provided by Dr. Richard Pyles (UTMB, Galveston, TX), and used for all studies. Stocks were prepared from infected Vero cell monolayers and frozen at −80°C. Vero cell monolayers (ATCC CCL-81) were grown in Dulbecco's modified Eagle's medium (DMEM; Corning, Manassas, VA) as previously described [36] . All HSV-2 infections in vitro were performed at a multiplicity of infection (MOI) of 0.1 (1 × 10 4 -5 × 10 4 PFU/ml depending on 3-D cell density in individual experiments). Virus titers were quantified by standard plaque assay using Vero cell monolayers as previously described [37] . The University of Arizona (UA) Institutional Biosafety Committee (IBC) approved all safety and handling of HSV-2 in the laboratory.
In vitro cytokine and TLR agonist treatment
Three-dimensional aggregates were treated with poly(I:C) (Invivogen, San Diego, CA) at 100 µg/ml, recombinant human IL-36γ (Peprotech, Rocky Hill, NJ) at 100 or 500 ng/ml as previously described [12] , or recombinant IL-36Ra (BioLegend, San Diego, CA) at 100 ng/ml. These concentrations are consistent with prior reports in the literature studying IL-36γ in the lung, skin, and intestines [25, [38] [39] [40] [41] . Aggregates were treated with acyclovir (ACV; GlaxoSmithKline, Research Triangle Park, NC) at 20 µg/ml as a positive control, or left untreated as a negative control.
Genital HSV-2 mouse model
Female six-to eight-week-old C57Bl/6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). All animals were housed in accordance with American Association for Laboratory Animal Care (AALAC) standards, provided unlimited access to food and water, and all procedures and handling for this study were approved by the UA Institutional Animal Care and Use Committee (IACUC) and performed in accordance with the Animal Welfare Act to minimize pain and suffering. Animals were acclimated for 7 days before being grouped (n = 5-10, groupings described in figure legends) prior to treatment and HSV-2 infection. All mice were pretreated with medroxyprogesterone acetate (1 mg/mouse; Up John Company, Kalamazoo, MI) at day -7 and day -1 as previously described [37] . Mice were i.vag. treated by instilling recombinant murine IL-36γ (100 ng, 250 ng, or 500 ng; BioLegend) or PBS (Corning, Manassas, VA) in 10 µl total volume. Mice were i.vag. challenged with HSV-2 186 (1 × 10 3 or 1 × 10 4 PFU) in 10 µl total volume in DMEM media as previously described [37] . Survival and disease incidence in mice were measured over a 21-day period. The vaginal mucosa was visually inspected daily for hair loss, erythema, and ulceration by the trained investigators in the study. Disease severity was scored daily according to the following scale: no pathology (0), mild vulvar erythema (1), moderate vulvar erythema (2), severe vulvar erythema and hair loss (3), perineal ulceration (4), extension of perineal ulceration to surrounding tissue and/or hind limb paralysis (5) . Moribund mice and those scoring a 5 were euthanized to minimize pain and suffering. Mice scoring a 4 that were euthanized were scored a 5 the following day. Disease onset/incidence was defined by erythema and hair loss (a score of 3). Vaginal swabs were collected at 2 and 3 days post inoculation (d.p.i.) using sterile urethro-genital calcium alginate tipped swabs (Puritan; Guilford, ME) in 1 mL DMEM stored at -80°C. Vaginal viral replication was measured in vaginal swabs by standard plaque assay as described.
IL-36γ treatment in mice
Mice were pretreated with medroxyprogesterone acetate as described above and then treated by i.vag. instillation with recombinant murine IL-36γ (250 ng or 500 ng; BioLegend) in 10 µl total volume.
Control mock-treated mice were administered 10 µl PBS. Vaginal lavages were collected from mice by i.vag. instilling 125 µl of sterile PBS and lavaging the vaginal cavity using an oral feeding tube (Fisher Scientific, Waltham, MA). Lavage fluid was stored at −80°C until cytometric bead array analysis. Female reproductive tract tissue was collected at 4 h and 24 h after treatment and stored in DNA/RNA Shield (Zymo Research, Irvine, CA) at −20°C until RNA extraction and qRT-PCR analysis.
Vaginal smears
Mice were conditioned with medroxyprogesterone acetate and treated with recombinant murine IL-36γ (250 ng; BioLegend) or mocktreated with PBS as described above. Four hours and 24 h after treatment mice were swabbed with a PBS soaked urethro-genital calcium alginate tipped swab (Puritan). Swabs were smeared on Fisherbrand Selectfrost microscope slides (Fisher Scientific) and allowed to air dry. Slides were stained with modified Wright stain (Volu-Sol, Salt Lake City, UT) and imaged on a Zeiss AxioImager M2 (Zeiss, Oberkochen, Germany) at 20× and 40× magnification to identify cell populations. Cell counting was performed by selecting five unique fields on a smear at 20× magnification. The number of epithelial cells, PMN, and total cells in each field were enumerated for each mouse in the treatment groups and the average count/mm 2 was calculated. The field of view at 20× magnification has an area of 1 mm 2 .
RNA extraction and qRT-PCR analysis
RNA was extracted from 3-D V19I aggregates and mouse FRT tissue using the Zymo Quick-RNA kit following the manufacturer's instructions (Zymo Research). Mouse FRT tissue was stored in DNA/RNA shield prior to RNA extraction. cDNA was synthesized from 1 µg RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and then analyzed by qRT-PCR using iTAQ Universal SYBR Green Supermix (BioRad). qRT-PCR was performed with an Applied Biosystems QuantStudio6 Flex Real Time PCR System (Life Technologies). Gene expression was normalized to GAPDH and fold change was calculated relative to controls. Primers used for all qRT-PCR analyses are listed in Table 1 .
Initial gene expression screens were performed using cDNA synthesized using a RT2 First-Strand kit (Qiagen, Valencia, CA) from 500 ng pooled RNA from murine FRT tissue treated with IL-36γ (500 ng) or PBS collected 4 h and 24 h after exposure and analyzed using Mouse Antiviral response and Mouse Toll-like receptor signaling RT2 arrays (Qiagen). qRT-PCR was performed as described above. Fold change was calculated by delta delta Ct analysis using RT2 Profiler PCR Array Data Analysis software (v3.5) and then log2 transformed (Qiagen).
Cytometric bead array analysis of CVLs
Cytokine levels in murine vaginal lavages were measured by cytometric bead array analysis using a Mouse High Sensitivity T Cell Magnetic Bead Panel (containing IL-1α, IL-1β, IL-6, TNFα, CCL20, and CXCL1/keratinocyte chemoattractant (KC)) and a Mouse Cytokine/ Chemokine Magnetic Bead Panel (containing IL-1β, IL-6, TNFα, IP-10, and KC) following the manufacturer's protocol (Millipore Sigma, Billerica, MA). Assays were performed using a Bio-Plex 200 system with Bio-Plex 5.0 Manager software (Bio-Rad).
Statistics
Disease incidence and survival in mouse models were analyzed by log-rank analysis as previously described [37] . Disease severity and resolution were analyzed by Area Under Curve (AUC) analysis with an unpaired two-tailed Student t-test with Welch's correction. Unpaired two-tailed Student t-test with Welch's correction, one-way ANOVA with Bonferroni's multiple comparisons test, and two-way ANOVA with Bonferroni's multiple comparisons test were performed for comparisons as indicated using Prism software version 7 (GraphPad, San Diego, CA). A P value of < 0.05 was considered significant.
Results
IL-36γ is induced by HSV-2, and treatment with IL-36γ limits HSV-2 infection in human 3-D VEC
Microbial products, including the viral mimic poly(I:C), have been shown to induce expression of IL36G mRNA and protein [12, 25, 27, 28] . To determine if HSV-2 infection induces mRNA expression of IL-36 family members, 3-D human VEC were challenged with HSV-2 186 (MOI of 0.1) or treated with poly(I:C) (100 µg/ml). Aggregates were collected after 4 h, and expression of IL-36α, IL-36β, IL-36γ, IL-36R (IL1RL2), and IL-36Ra (IL36RN) mRNA transcripts was measured by Table 1 Primers used in this study.
qRT-PCR. HSV-2 infection significantly (P < 0.01) induced expression of IL36G 6.5-fold relative to untreated controls (Fig. 1A) . Expression of other IL-36 family member gene transcripts were not significantly altered after HSV-2 infection, suggesting that IL-36γ may play an important role in antiviral host defense in the FRT. The induction of IL36G after HSV-2 infection was similar to poly(I:C) treatment, a viral RNA mimic, and known inducer of IL-36γ (Fig. 1B) . As a potential host defense mechanism in response to HSV-2 infection, we sought to determine the level to which IL-36γ impacted HSV-2 replication in a well-characterized 3-D human VEC model [33] . Threedimensional VEC aggregates were treated with IL-36γ (100 ng/ml or 500 ng/ml) or poly(I:C) (100 µg/ml) 24 h prior or 4 h prior to HSV-2 challenge. Aggregates were treated with acyclovir (ACV; 20 µg/ml) 2 h prior to infection as a positive control to limit HSV-2 replication, or left untreated as a negative control. Twenty-four hours post inoculation, viral titers were measured by standard plaque assay. Treatment with IL-36γ (100 ng/ml) both 24 h and 4 h prior to infection resulted in a significant (P < 0.05) reduction in viral titers compared to untreated controls (Fig. 1C ). Exposure to a higher dose of IL-36γ (500 ng/ml) 24 h or 4 h prior to infection reduced viral titers similar to treatment with IL-36γ at 100 ng/ml. Poly(I:C) treatment also significantly (P < 0.01) reduced viral titers similar to IL-36γ treatments at both time points. The relatively short half-life of ACV [42] [43] [44] , the administration of a single dose of ACV over a 24 h period [44] , and the high infectious dose (1 × 10 4 -5 × 10 4 PFU) used in this study may explain the incomplete blockade of HSV-2 replication beyond the measured ∼ 50-fold reduction. IL-36 signaling through IL-36R was blocked by treating 3-D human VEC with recombinant IL-36 receptor antagonist (IL-36Ra), and inhibition of IL-36γ signaling was confirmed by qRT-PCR (data not shown). Pretreatment with IL-36Ra (100 ng/ml) prior to HSV-2 challenge did not significantly increase viral titers relative to controls, suggesting that other mechanisms (e.g. NFκB activation, Type I IFN) may compensate to control HSV-2 infection in human VEC (Supplemental Fig. 1 ). To extend these findings, we sought to understand the role of IL-36γ in the context of HSV-2 disease pathogenesis in a complex multicellular microenvironment using a well-established animal model. Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.cyto.2018.07.034.
Treatment with IL-36γ limits vaginal viral replication, delays disease onset, and decreases disease severity to protect against lethal HSV-2 challenge
To determine the extent to which IL-36γ exposure limits HSV-2 disease pathogenesis, female C57Bl/6 mice were treated with IL-36γ prior to lethal HSV-2 challenge. In initial studies to examine the impact of IL-36γ dose on HSV-2 disease, medroxyprogesterone acetate conditioned mice were i.vag. treated with recombinant murine IL-36γ (100 ng, 250 ng, or 500 ng) or mock treated with PBS (n = 5-10/group) 4 h prior to lethal HSV-2 challenge with a rigorous challenge dose of 1 × 10 4 PFU (35× LD 50 ). We found that mice treated with IL-36γ
(250 ng) 4 h prior to infection had a significant (P < 0.0001) delay in disease onset, and survived significantly (P < 0.0001) longer relative to PBS controls (Supplemental Table 1 ). Similar to mice treated with the 250 ng dose, mice treated with IL-36γ (500 ng) exhibited a significant (P < 0.0001) delay in symptoms, and increased survival time compared to controls. However, there was no difference in the time to symptoms or survival time between mice that were treated with IL-36γ (100 ng) and controls. Further, when mice were treated with IL-36γ (250 ng) 24 h prior to lethal challenge, there was no difference in disease onset or survival time relative to controls. These initial studies demonstrated that both the dose of IL-36γ and timing of delivery are important in limiting HSV-2 disease. We then sought to determine the impact of IL-36γ treatment on HSV-2 disease pathogenesis using a lower challenge dose (LD 100 ) previously reported [37, 45, 46] . Medroxyprogesterone acetate conditioned mice were i.vag. treated with IL-36γ (250 ng) or mock-treated with PBS (n = 10/group) 4 h prior to challenge with 1 × 10 3 PFU HSV-2 186
(LD 100 ). Vaginal viral titers were measured in vaginal swabs collected 2 and 3 days post-inoculation (d.p.i.). Vaginal viral titers were significantly (P < 0.0001) reduced in mice treated with IL-36γ compared to PBS controls on both day 2 and 3p.i., and several IL-36γ treated mice had no detectable titers at either 2 or 3 d.p.i. (Fig. 2A) . Survival and disease incidence was measured over a 21-day period and the disease severity was recorded daily on a 1-5 scale to monitor disease progression. IL-36γ treated mice had significantly (P < 0.01) less severe disease relative to PBS controls, and 3/20 (15%) IL-36γ treated mice Aggregates were treated with acyclovir (20 µg/ml) 2 h prior to infection as a positive control. Viral titers were measured after 24 h as PFU/ml by standard plaque assay. Dashed line indicates limit of detection for assay. Data represent mean ± SD from biological replicates from three independent experiments. Statistical significance was determined by one-way ANOVA with Bonferroni's multiple comparisons test (A, B) and two-way ANOVA with Bonferroni's multiple comparisons test (C). ** P < 0.01; *** P < 0.001; **** P < 0.0001. exhibited no disease symptoms over the 21-day period (Fig. 2B) . Of the 17 IL-36γ treated mice that developed disease, five mice (29.4%) exhibited less severe pathology that did not progress in severity beyond a score of 2/5. Treatment with IL-36γ significantly (P < 0.0001) delayed the onset of disease, and reduced the number of mice presenting both hair loss and erythema at the introitus and surrounding tissue to just 12/20 (60%), compared to 20/20 (100%) of mice in the PBS group (Fig. 2C) . In the IL-36γ treated mice that did develop erythema and hair loss, onset was delayed by two days compared to controls. Moreover, IL-36γ treatment significantly (P < 0.0001) protected from lethal challenge, as 8/20 (40%) of IL-36γ treated mice survived, whereas 20/ 20 (100%) of PBS treated mice succumbed to disease (Fig. 2D) . IL-36γ treated mice that died from lethal infection exhibited a three-day delay in death. These data demonstrate that IL-36γ treatment limits viral replication, decreases disease severity, and increases survival, suggesting that IL-36γ enhances protection against a lethal HSV-2 challenge in the vaginal epithelium.
IL-36γ drives the transient production of immune mediators in murine lower FRT tissue and vaginal lavages
Previously, we have demonstrated that IL-36γ induces expression and secretion of pro-inflammatory cytokines and chemokines 24 h after treatment in a human 3-D VEC model [12] , and this may be a mechanism whereby IL-36γ treatment can limit HSV-2 replication and disease. In an initial screen, we employed gene expression arrays to assay over 130 unique genes involved in the antiviral response and Tolllike receptor signaling to identify key immunoregulatory genes that could be modulated by IL-36γ exposure in murine FRT tissue. We collected FRT tissue from mice treated with IL-36γ (500 ng) or mocktreated with PBS 4 h and 24 h after exposure, and pooled RNA from mice in the treatment groups for cDNA synthesis and analysis. From this initial screen (Supplemental Fig. 2 ), we identified several cytokines, chemokines and immune signaling molecules that were upregulated in the murine FRT 4 h after treatment with IL-36γ to further investigate and validate. Many of these genes have been shown to be important in the immune response to HSV-2 [47] [48] [49] [50] [51] . We also identified several antimicrobial peptides (AMP) that have previously been demonstrated to limit HSV-2 infection [8] [9] [10] that were not included in the arrays for subsequent analysis.
Murine lower FRT tissue was collected 4 h and 24 h after treatment (n = 5/time point) with IL-36γ (250 ng) and qRT-PCR was performed. We measured a transient induction of the IL-1 family members Il1b and Il36g 4 h after treatment with IL-36γ, with levels increased 7.7-fold and 12.9-fold, respectively (Fig. 3A) . Levels of Il1b and Il36g decreased by 24 h treatment, and were induced 1.8-fold and 2.5-fold, respectively. Expression of the cytokine IL-6, in contrast, was significantly (P < 0.01) increased 4.6-fold 24 h after IL-36γ treatment. Levels of the chemokines Ccl20 and Cxcl1 (KC) were transiently increased 4 h after treatment 9-fold and 5.9-fold respectively, and levels decreased by 24 h after treatment. Additional chemokines were initially screened in the gene expression arrays, including Ccl2, Ccl3, Ccl4, Ccl5, Csf2, Csf3, and expression of these targets was not significantly altered by IL-36γ treatment (Supplemental Fig. 2 ). In addition to cytokines and chemokines, we measured levels of the AMP defensin beta 3 (Defb3), lactotransferrin (Ltf), and secretory leukocyte peptidase inhibitor (Slpi). Slpi was transiently induced, with levels at 4 h after treatment significantly (P < 0.05) increased 4.8-fold relative to PBS controls. No significant changes in expression of Defb or Ltf was observed. Interestingly, the Ctype lectin, Clec4e, was robustly induced 24.8-fold 4 h after IL-36γ exposure, and at 24 h after treatment Clec4e expression was increased 6.4-fold relative to controls. We observed no significant changes in expression of the mucin Muc13 and the inflammasome component Nlrp3 at either 4 h or 24 h after IL-36γ exposure. Altogether, these data demonstrate that IL-36γ induces the transient expression of immune mediators at 4 h in the murine FRT that may contribute to resistance to genital HSV-2 disease.
To understand the kinetics of cytokine and chemokine secretion Fig. 2 . IL-36γ treatment 4 h prior to infection significantly protects against HSV-2 disease incidence, reduces disease severity, and enhances survival. Female six-to eightweek-old C57Bl/6 mice were treated with murine recombinant IL-36γ (250 ng) 4 h prior to infection (n = 10), or mock-treated with PBS (n = 10). Mice were then intravaginally challenged with a lethal dose of HSV-2 186 (10 3 PFU). (A) Vaginal swabs were collected at days 2 and 3 post-inoculation and HSV-2 replication was measured in duplicate by standard plaque assay. Each symbol represents an individual mouse, and mean ± SD is depicted. Dashed line represents minimum detectable level for assay. Several IL-36γ-treated mice had undetectable titers and are depicted on the graph as half of the minimum detectable level. Disease severity (B) was measured daily and scored on a 0-5 scale. Once a mouse scored 5 and died it was no longer included in scoring. Incidence of disease was measured by the presence of both erythema and hair loss (C), and survival (D) was recorded over a 21-day period. Data is representative of two independent animal studies. Statistical analyses were performed by one-way ANOVA with Bonferroni's multiple comparisons test (A), Area Under Curve (AUC) analysis with an unpaired twotailed Student t-test with Welch's correction (B), and log-rank analysis (C, D). ** P < 0.01; **** P < 0.0001.
J.K. Gardner, M.M. Herbst-Kralovetz
Cytokine 111 (2018) [63] [64] [65] [66] [67] [68] [69] [70] [71] following IL-36γ treatment, murine vaginal lavages were evaluated by cytometric bead array analysis to measure protein levels of soluble immune mediators. Vaginal lavages were collected from mice treated i.vag. with recombinant murine IL-36γ (250 ng) or PBS in the absence of HSV-2 challenge. Levels of cytokines (IL-1α, IL-1β, IL-6, TNFα) and chemokines (CCL20, KC, IP-10) shown to be important in limiting HSV-2 infection were evaluated in lavages at 4, 24, and 48 h after treatment (n = 5/time point) using a high sensitivity murine cytokine/chemokine panel. IL-36γ significantly (P < 0.05) increased CCL20 levels 62-fold compared to PBS controls 4 h after treatment (Fig. 3B) . IP-10 levels were increased 4 h after IL-36γ treatment, but at a lower fold induction (5-fold). Likewise, IL-36γ treatment significantly (P < 0.01) increased KC levels 11-fold compared to PBS controls at 4 h. By 24 h after treatment, levels of chemokines were lower when compared to 4 h, and returned to baseline levels by 48 h. The cytokines IL-1α, IL-1β, IL-6, and TNFα were not significantly induced relative to PBS controls at all time points (data not shown). Overall, these results demonstrate a significant transient increase in chemokine secretion following IL-36γ treatment in murine vaginal lavages that correlated with gene expression data ( Fig. 3A and B) and may have contributed to limiting HSV-2 replication and increasing survival.
IL-36γ promotes the transient recruitment of neutrophils in the local vaginal microenvironment
The high levels of chemokines measured in vaginal lavages and murine FRT tissue following IL-36γ treatment led us to investigate the extent to which IL-36γ treatment impacted immune cell infiltration in the lower FRT. Medroxyprogesterone acetate-conditioned female C57Bl/6 mice were treated i.vag. with recombinant murine IL-36γ (250 ng) or PBS. Vaginal swabs were collected 4 h and 24 h following treatment (n = 5/treatment), and smeared on slides and allowed to air dry. Slides were then stained with modified Wright stain and imaged to characterize immune cell infiltration. Treatment with IL-36γ significantly (P < 0.01) enhanced infiltration of polymorphonuclear leukocytes (PMNs) (shown by black arrows) in vaginal smears 7.7-fold relative to PBS controls at 4 h post-treatment (Fig. 4) . There was a homogenous infiltration of cells that consistently exhibited PMN morphology. The increase in PMNs corresponded with the elevated levels of the chemokines CCL20 and KC after IL-36γ treatment that recruit PMN, as well as the induction of IP-10, a chemokine produced by PMN. PMN infiltration decreased by 24 h post-treatment, and was comparable to PBS controls. Epithelial cells were present in vaginal swabs from both *** P < 0.005; ****P < 0.0001 treatment groups, albeit at lower levels relative to PMNs. This could be due to the progesterone treatment all mice received, which has been demonstrated to thin the vaginal epithelium, and mice remain in diestrus for at least one month [52, 53] . Together, the enhanced recruitment of PMNs following IL-36γ treatment could be a potential mechanism whereby IL-36γ treatment protects against genital HSV-2 disease.
Discussion
We have previously demonstrated that IL-36γ is expressed in FRT tissue, and promotes the secretion of cytokines, chemokines and AMP in response to microbial products [12] . In addition, recent proteomic studies evaluating human CVLs have found an increased relative abundance of IL-36γ in women with bacterial vaginosis and HSV-2 seropositive women using the contraceptive Depo-Provera [31, 32] . In this report, we investigated the role of IL-36γ in the vaginal microenvironment and in protecting against a prototypical viral STI, HSV-2. Herein we demonstrated that IL-36γ treatment can limit HSV-2 replication, decrease disease severity, and protect against a lethal HSV-2 challenge.
Early in infections, microbial products trigger TLRs in the vaginal epithelium [54] and stimulate the innate immune response. In HSV-2 infections, envelope glycoproteins will be sensed by TLR2, whereas the nucleic acid sensing TLR3 and TLR9 will be triggered by viral nucleic acid products during HSV replication [55, 56] . Poly(I:C), a viral dsRNA mimic, has previously been shown to protect against lethal HSV-2 challenge [37] , and induce IL-36γ in vitro [12, 25, 27, 28] , suggesting that IL-36γ could participate in antiviral host defense. Herein, we demonstrated that HSV-2 infection robustly induced IL36G expression, but did not significantly alter expression of other IL-36 family members. This finding suggests that IL-36γ, specifically, may play a key role in antiviral host defense in the vaginal epithelium. Induction of IL-36γ in response to HSV-2 may be TLR-mediated, as TLR2, TLR3, and TLR9 are all stimulated during HSV infection [56] .
We investigated the role of IL-36γ in the FRT and innate immune mechanisms that can contribute to the inflammatory response during acute HSV-2 infections that may influence virus replication and, ultimately, disease pathogenesis. Data from both our in vitro and in vivo models suggest that IL-36γ may limit HSV-2 replication and disease through multiple innate immune mechanisms. We have previously demonstrated that exposure to IL-36γ for 24 h promotes the production of the pro-inflammatory cytokines IL-1α, IL-1β, IL-6, and TNFα in VEC [12] . In IL-36γ treated murine FRT tissue we also observed an increase in expression of Il1a and Il1b however, this was a more transient induction with levels the highest after exposure for 4 h (Fig. 3A) . IL-1α and IL-1β are important pro-inflammatory cytokines that have been shown to regulate HSV replication and disease and may be contributing to the antiviral environment we observed after IL-36γ treatment [48] [49] [50] [57] [58] [59] . AMP, including Slpi, Defb3, and Ltf, are also key soluble immune mediators that have been shown to inhibit HSV infection [8] [9] [10] , and are induced by IL-36γ in human VEC [12] . Likewise, we measured elevated levels of Slpi following IL-36γ treatment in murine FRT tissue (Fig. 3) . Interestingly, IL-36γ exposure significantly increased expression of the C-type lectin Clec4e 24-fold (Fig. 3A) . While C-type lectin receptors (CLR) are mostly known for their role in antifungal immunity, there is evidence of CLRs protecting against viral infection, including HSV-1 [60, 61] . Future studies are required to determine if Clec4e can contribute in host defense against genital HSV-2 infection. Collectively, increased production of these immune mediators may contribute to the HSV-resistant environment that is induced by IL-36γ treatment to limit viral replication and enhance survival.
In the complex multicellular vaginal microenvironment, innate immune cells can also contribute to enhanced resistance to genital HSV-2 infection, control viral replication and clear infections. Signaling by IL-36γ and IL-36R has previously been shown to increase chemokine levels and promote leukocyte recruitment in both the skin and lungs [14, [62] [63] [64] . Indeed, we observed that IL-36γ exposure elicited significantly increased levels of the chemokines CCL20 and KC measured in both FRT tissue and vaginal lavages 4 h following treatment (Fig. 3) . KC and CCL20 can both function to recruit polymorphonuclear leukocytes (PMN), including neutrophils, that are important for protection against HSV infection in animal models [51, [65] [66] [67] . HSV-2 infection does promote the recruitment of PMN in the FRT; however, this is not until approximately 24 h after infection [65, 68] . We observed an increase in the recruitment of PMN in vaginal smears collected from mice 4 h after treatment with IL-36γ that corresponded with increased levels CCL20 and KC measured in vaginal lavages (Figs. 3B and 4) . Vaginal smears contained a homogenous infiltration of cells that were consistent with PMN morphology, however, other immune cell populations were not morphologically identified from either IL-36γ treated or control animals. Further, we did not measure a significant induction in chemokines that recruit monocytes/macrophages (Ccl2, Ccl3, Ccl5), basophils (Ccl2), eosinophils (Ccl5), T-cells (Ccl3, Ccl4, Ccl5, Cxcl9, Cxcl11), NK cells (Ccl4,), and other immune cell populations. This suggests that these cells are not being recruited to the vaginal microenvironment at 4 h or 24 h after IL-36γ treatment, which was further supported by the vaginal smears. However, the presence and contribution of other immune cell subsets cannot be ruled out and require additional analyses. PMN have been shown to be important in suppressing viral replication [65] , and our data suggest that the increase of PMN in the vaginal epithelium may contribute to the decreased levels of vaginal viral replication we measured in IL-36γ treated mice ( Figs. 2A and 4) . Neutrophils are important producers of proteases, including elastase, which has recently been shown to cleave and activate IL-36γ [69] . Therefore, IL-36γ-mediated neutrophil recruitment could increase levels of elastase, and enhance cleavage and activity of IL-36γ. Another important function of PMN is the production of soluble immune mediators, including AMP and other chemokines that could contribute to the HSV-resistant environment induced following IL-36γ treatment. An important chemokine produced by PMN is IP-10, a T-cell chemoattractant that contributes to controlling HSV replication in vivo [70] [71] [72] . We measured elevated levels of IP-10 (5-fold) in vaginal lavages 4 h after IL-36γ treatment, that corresponded with increased CCL20 and KC levels at the same time point (Fig. 3B) . The robust induction of CCL20 and KC that we measured could be key in recruiting PMN early to combat genital HSV-2 infection in the FRT by decreasing disease severity, promoting disease resolution, and enhancing survival following a lethal viral challenge. Previously, we demonstrated that microbial products stimulate IL-36γ in human models of the FRT and that IL-36γ could regulate host defense mechanisms at this site [12] . We extend these findings here in the context of a highly relevant STI pathogen, HSV-2. Consistent with a recent clinical report, we found that HSV-2 robustly induces IL-36γ [29] . Furthermore, we found that pretreatment with IL-36γ significantly decreased vaginal viral replication in vitro. This translated to significantly limiting vaginal viral replication, decreasing disease severity and incidence, and increasing survival in a lethal HSV-2 mouse model. In summary, our data suggests that IL-36γ exposure induces a HSV-2 resistant environment through the transient induction of cytokines and chemokines that can inhibit viral replication and promote PMN recruitment in the vaginal microenvironment to protect against genital HSV-2 disease. The animal model dependence on the dose and timing of IL-36γ delivery facilitates the pursuit of future studies to investigate both IL-36-mediated protection in the FRT and the translational impact of these findings. Our data indicate that IL-36γ functions as a key regulator of innate immune signaling in genital HSV-2 infection and may play a role in host defense against other STI pathogens in the FRT.
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